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A B S T R A C T
In this study, we aimed to provide molecular evidence of HPV latency in humans and discuss potential challenges
of conducting studies on latency. We analyzed the entire cervix of two women who underwent hysterectomy
unrelated to cervical abnormality. The cervices were sectioned into 242 and 186 sets respectively, and each set was
tested separately for HPV using the SPF10-PCR-DEIA-LiPA25 system. To identify whether there was any evidence
of transforming or productive infection, we used the biomarkers E4 and P16INK4a to stain slides immediately
adjacent to HPV-positive sections. HPV was detected in both cervices. In patient 1, 1/242 sets was positive for
HPV31. In patient 2, 13/186 sets were positive for HPV18 and 1/186 was positive for HPV53. The infection was
very focal in both patients, and there was no sign of a transforming or productive infection, as evaluated by the
markers E4 and P16INK4a. Had we only analyzed one set from each block, the probability of detecting the infection
would have been 32.3% and 2%, respectively.Our findings support the idea that HPV may be able to establish
latency in the human cervix; however, the risk associated with a latent HPV infection remains unclear.
1. Introduction
For several years, there has been discussion as to whether or not
human papillomavirus (HPV) is able to establish latency in the epi-
thelium of the human uterine cervix [1–4], with the possibility of viral
reactivation during periods of immune deficiency [5]. Despite evidence
from clinical studies, such as the reporting of HPV re-appearance fol-
lowing an HPV-negative test result [6–9] in sexually abstinent women
and a higher risk of HPV-related disease in immune suppressed in-
dividuals, including organ transplant recipients [10] and HIV ser-
opositive patients [11,12], there is still no consensus in the scientific
community on whether or not HPV is able to establish latency. If HPV is
able to establish latency in humans, the viral genome would be ex-
pected to be maintained in the basal epithelial cell layer of stratified
epithelium, with no shedding of viral particles and without clinical
evidence of disease, similar to what has been reported in the animal
model [3,5]. Moreover, the infection may be focal, and be characterized
by low HPV DNA copy number and possibly also a low number of in-
fected cells [13]. These characteristics provide a challenge for the de-
tection of a latent HPV infection, and may explain why a latent HPV
infection is not picked up by routine HPV testing of cervical cytology
samples. In cervical cytology samples, only the superficial cell layer is
sampled for HPV testing. The detection of a latent HPV infection is
likely to be facilitated by the use of samples that include the basal
epithelial cell layer, such as tissue sections from the cervix. Further-
more, an intensive sampling procedure may be required in human
studies to ensure detection, as there is no tattoo ink to guide us to the
site of previous infection, unlike in the animal model [3]. In the present
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study, we have taken these considerations into account, and have aimed
to provide molecular evidence of HPV latency in the human uterine
cervix, along with a discussion of the challenges of conducting studies
on HPV latency in humans.
2. Material and methods
For the present study, we selected two women considered at high
risk of harboring a latent HPV infection based on their previous ex-
posure to HPV (i.e.,> 10 life time sex partners) and because they had a
record of a previous abnormal cervical cytology (i.e., atypical squamous
cells of undetermined significance or worse), which had not been sur-
gically treated. These women were selected from a group of women
who had their cervix removed as part of total hysterectomy unrelated to
epithelial abnormality of the cervix such as bleeding disorders, fi-
bromas, and prolapse at the Department of Obstetrics and Gynecology,
Aarhus University Hospital, from March 1st, 2013 through April 1st,
2015. Prior to surgery, both patients had a normal cervical cytology and
were HPV-negative on routine testing using COBAS 4800® (Roche
Molecular Diagnostics). After surgical removal, an experienced gyne-
cological pathologist reviewed hematoxylin and eosin (H&E) stained
cervical tissue slides by routine bright field microscopy and found no
evidence of HPV infection, cervical neoplasia, or other disease.
Fig. 1 illustrates the processing of cervical samples. After surgical
removal, the cervix was separated from the uterine corpus (a) and sliced
open in the anterior wall. The cervix was fixed to a styrofoam plate
covered with a sterile glove (b) and subsequently fixed with formalin for
approximately 24 h. The following day, the cervix was cut into 3-mm
sections (c) and embedded in paraffin. To avoid cross-contamination, we
used sterile utensils only (i.e., gloves, syringes, scalpels, etc.).
After the procedure described in Fig. 1, the entire cervix was sectioned
in both patients, as illustrated in Fig. 2, resulting in up to 30 sets per
formalin fixed, paraffin embedded block; a set consists of one section of
4 µm for H&E, 3 sections of 8 µm for whole tissue SPF10 PCR, and four
unstained sections of 4 µm for further analyses. To check for changes
characteristic of viral infection, H&E slides adjacent to HPV-positive slides
underwent additional review by a pathologist experienced in routing di-
agnostic gynecological pathology at DDL diagnostic Laboratory.
DNA extraction of tissue samples was performed using a proteinase
K procedure as described previously [14]. For cytological samples, DNA
was isolated from 200 μL Surepath suspension (Becton Dickinson and
company, Franklin, NJ, USA), containing exfoliated cervical cells, using
the MagNA Pure LC instrument as described elsewhere [15]. HPV
analyses were performed using the SPF10-PCR-DEIA-LiPA25 system
(SPF10 HPV LiPA25 version 1; Labo Bio-Medical Products, Rijswijk,
The Netherlands) as described previously [16,17]. The DEIA is an
ELISA-based assay that allows detection of at least 69 HPV types,
whereas the LiPA25 allows qualitative identification of the following
25 HPV genotypes: 6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45,
51, 52, 53, 54, 56, 58, 59, 66, 68/73, 70, and 74.
During the testing, extensive measures were taken to avoid cross-
contamination. Thus, controls were incorporated in all phases of the
testing and all controls were tested in the DEIA. 1) The sectioning in-
cluded the cutting of an empty paraffin block at the beginning and at
the end of each block, and after every 10 sets (Fig. 2). 2) Each DNA
extraction run included two negative controls and one positive control.
3) The PCR included a negative and a positive control. 4) The DEIA
included a negative, a borderline (to establish the cut-off for positivity),
and a positive control. 5) The LiPA25 contained a positive control,
which was the PCR positive control. Amplification failure or con-
tamination was not observed. All HPV analyses were performed at DDL
Diagnostic Laboratory, the Netherlands.
2.1. P16 immunohistochemistry and E4 immunofluorescence
Sections adjacent to HPV-positive slides were subject to further
analysis with the purpose of localizing the infection and explore po-
tential evidence of an HPV infection. P16INK4a staining was performed
on the first adjacent slide in each HPV-positive set as this marker is
commonly used as a biomarker of transforming HPV infections. The
p16INK4a staining was performed using the CINtec system as described
elsewhere [18]. For the present study we used p16INK4a positive tissue
as internal control. Each slide contained the study tissue section as well
as a section from a CIN3 (cervical intraepithelial neoplasia grade 3 or
worse) lesion known to be p16INK4a positive.
Furthermore, we used a recently developed pan HPVE4 antibody
(SILgrade-E4-1 kit containing XR-E4-1 monoclonal antibody, Labo Bio-
medical Products, Rijswijk, The Netherlands) able to detect the E4
proteins of at least 15 types of high-risk HPV (including HPV16, 18, 31,
33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, and 70) [18] on the second
adjacent slide. The HPV E4 protein is expressed in infected squamous
cells that have initiated the productive stage of the viral life cycle
[19–21], which occurs primarily in low-grade disease [22]. The E4
marker can be detected using conventional immunohistochemistry or
immunofluorescence approaches [18], but in this study we used an
immunofluorescence as outlined in previous studies [22,23]. Briefly,
4 µm sections from HPV-positive sets were dried over night at 37 °C,
deparaffinized in xylene, and rehydrated in a descending alcohol series.
For epitope retrieval, slides were autoclaved in solution D, Ph 6.0
(Dako, Glostrup, Denmark) at 121 °C for 2min. The antibodies against
Fig. 1. Overview of the sampling procedure.
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E4 (panHPVE4) were applied 1:100 and incubated over night at 4 °C.
Visualization was performed with 150-fold diluted Alexa-488 (green)
conjugated anti-mouse secondary antibody against E4 (Invitrogen,
Paisley, UK). Finally, a nuclear counterstaining was performed using
DAPI (blue) (Sigma, St. Louis, MO, USA). A CIN1 known to be caused by
HPV16 was used as a positive control and gave the characteristic pat-
tern of E4 staining as described previously [20,22]. P16INK4a staining
was performed at DDL, Diagnostic Laboratory, The Netherlands,
whereas the panHPVE4 staining was performed at the Department of
Pathology, University of Cambridge, UK.
We defined possible viral latency as follows: HPV detected in the
tissue with no evidence of E4 and p16INK4a positivity, no clinical or
histo-pathological evidence of disease, no cytological abnormality, and
HPV-negative on liquid based cytology.
2.2. Statistical analysis
We used our results of the density of latent HPV detection to esti-
mate the probability that a given cervix would yield an HPV-positive
result if only a sample of tissue was tested from each specimen block.
Assuming the results follow a binomial distribution, we calculated the
probability of detecting HPV in a given cervix as follows:=P (x 1) 1–(1–p)n
where P (x≥ 1) = probability that at least one sampled set tests po-
sitive, n= number of sets tested, and p=probability that a set con-
tained a latent HPV infection based on the results of our study.
The Danish Ethics Committee (1-10-72-432-12) and the Danish Data
Protection Agency (1-16-02-211-12) approved the study. Both patients
signed an informed consent form prior to enrollment.
3. Results
Both patients selected for the present study had a total laparoscopic
hysterectomy; patient 1 due to a bleeding disorder and patient 2 be-
cause of predisposition to ovarian cancer. Patient 1 was 52 years old
and premenopausal at the time of surgery, whereas patient 2 was 67
years old and postmenopausal. Patient 1 had 12 lifetime sex partners
and was in 1988 diagnosed with HSIL, for which she did not receive
surgical treatment. Patient 2 was diagnosed with ASC-H in 2010, which
could not be verified histologically, and she had 23 sex partners during
her life. Both patients reported no current or previous use of hormone
replacement therapy (Table 1). Additionally, both patients had no re-
cord of histologically verified cervical abnormality within 5 years of
hysterectomy.
HPV was detected in both patients when the entire cervix was
evaluated with the use of whole tissue PCR. In patient 1, a total of 9
blocks were sectioned into 186 sets. Seven of the nine blocks contained
HPV-positive sets. HPV-positive sets were mainly adjacent to HPV-
positive sets (Fig. 3). Of 186 sets tested, 13 sets (7.0%) were HPV18
positive and one set (0.5%) was positive for HPV53. In patient 2, a total
of 11 blocks were sectioned into 242 sets of which one set (0.4%) was
positive for HPV31, and one set was borderline positive on the DEIA.
However, because the borderline positive sample was negative by re-
verse hybridization using the LiPA25 strip, the sample was deemed HPV
negative, according to standard protocol.
Fig. 3 illustrates the distribution of HPV infection across the cervix.
The HPV infection was very focal in both cervices, but as a result of
more HPV-positive sets in patient 1, the infection appeared more
widespread in patient 1 compared to patient 2.
We carefully reviewed H&E-stained slides adjacent to HPV-positive
sections and found no evidence of a productive HPV infection by bright
field microscopy; i.e., no micro lesions, koilocytosis, dyskariotic cells,
etc. As cervical smears obtained prior to surgery were initially tested
using COBAS 4800, which has lower sensitivity, we re-tested the two
cervical cytology samples obtained prior to surgery using the SPF10-
PCR-DEIA-LiPA25 system, and both samples were HPV-negative.
To explore if HPV DNA positivity may be associated with a pro-
ductive viral infection, we tested adjacent slides to HPV-positive sets for
the presence of E4. While the positive controls stained strongly, all
adjacent slides to HPV-positive section were negative for E4.
Overexpression of the cellular biomarker p16 INK4a in cervical tissue
is usually associated with the presence of the viral oncogenes, E6 and
E7. All adjacent slides to HPV-positive slides were negative for p16
INK4a, while all positive and negative controls did not suggest a failure in
the analysis. The absence of E4 and p16 INK4a may therefore suggest that
the HPV infection detected represents a non-transforming and non-
productive infection, such as a latent HPV infection.
Acknowledging that the methodology applied in the present study
was very costly and time consuming and not feasible for use in future
Fig. 2. Overview of the sectioning protocol. One set consists of an H&E slide (4 µm), a tube with 3 sections for HPV PCR (PCR 3×8 µm), and 4 blank slides
(4× 1×4 µm) for additional analysis.
Table 1
Basic characteristics of the two patients selected for analysis.
Characteristics Patient 1 Patient 2
Age (years) 52 67
Previous abnormal cervical
cytology
HSIL in 1988, not
surgically treated
ASC-H in 2010,
normal histology
Number of life-time sex partners 12 23
Number of new sex partners by
age (years)
Age 13–19: 3 Age 13–19: 4
Age 20–29: 8 Age 20–29: 11
Age 30–39: 1 Age 30–39: 3
Age 40–49: 0 Age 40–49: 3
Age 50–59: 0 Age 50–59: 1
Age 60–69: 2
Number of blocks tested 9 11
Amount of tissue tested by
SPF10-PCR (μm)
4464 5808
Number of SPF10-PCR tests
performed
186 242
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studies, we used the results above to calculate the probability of de-
tecting HPV in a cervix if only a proportion of the total tissue is sampled
for PCR testing. Table 2 summarizes the probability of a cervix testing
HPV-positive by a range of proportion of HPV-positive sets (rows) and
proportion of the cervix analyzed (columns). In the present study, we
found 7.5% of sets were HPV-positive in patient 1. Thus, the probability
of an HPV-positive test result would be 32.3% had we only analyzed
one set from each block. In patient 2, 0.4% of sets were HPV-positive,
which equals to a 2% probability of an HPV-positive result if we only
analyzed one set from each block.
4. Discussion
Thus far, several clinical and epidemiological studies have sug-
gested that HPV is likely being controlled by the immune system rather
than cleared [1,4,24–26]. Such studies include the periodical shedding
of viral particles [27], the re-appearance of HPV following an HPV-
negative test [8], and the increase in HPV prevalence after the initiation
of immune suppression [25]. Although animal studies have shown that
papillomavirus DNA can be detected in a latent stage up to one year
after lesion regression, studies reporting molecular evidence of HPV
latency in the human uterine cervix are still lacking.
In the present study, HPV was detected in the human uterine cervix
in both patients, with no evidence of a productive or transforming in-
fection by immunohistochemistry and immunofluorescence, and
without clinical, cytological, or histopathological evidence of HPV-re-
lated disease. These findings may represent HPV infections below de-
tectable levels or possibly molecular evidence of HPV latency. Our re-
sults are consistent with previous animal studies in which
papillomavirus DNA and mRNA expression was detected in the mucosa
following an incident infection without there being evidence of clinical
disease [3,28]. It is unlikely that infections in this latent state pose any
immediate risk of severe disease as evidence by the lack of abnormal
pathology; however, it remains unclear whether future reactivation
from the latent state would result in disease risk similar to that observed
in young women with newly acquired infection.
In the animal models, tattoo ink is often used at the site of in-
oculation, which allows for the distinctive analyses of tissue known to
have been exposed to the virus [3,5,28]. In the human uterine cervix no
such marker exists. Additionally, results from the animal model suggest
that, during HPV latency, only a few basal epithelial cells may harbor
HPV DNA and at a very low copy number. These factors provide a
challenge for the detection of a latent HPV infection and highlight the
importance of using a highly sensitive HPV assay and an extensive
sampling procedure. In the animal model, viral latency was only de-
tected using a PCR-based technique as the viral copy number during
latency was too low to allow for visual detection by in situ hybridiza-
tion [3] using techniques available at the time of the study.
Due to the focal nature of a latent HPV infection as reported in the
animal model, we chose to perform an intensive sampling and testing
procedure on two patients who were considered at high risk of har-
boring a latent HPV infection (i.e., ≥ 10 life time sex partners and a
previous record of HPV related disease). This decision was based on
previous studies reporting that HPV detection at older age is more likely
attributed to previous and not recent sexual activity [9,29,30]. The
focal nature of the HPV infections observed in the present study sug-
gests that the infection may have been missed had we only analyzed
one section from each block. As reported in Table 2, an intense sam-
pling and testing procedure will be required to accurately determine the
presence or absence of a latent HPV infection.
To the best of our knowledge, only a few studies have reported
evidence of possible HPV latency in humans. Two studies analyzed
normal, HPV-positive cervical tissue with no signs of viral replication,
adjacent to a cervical lesion (i.e. cervical intraepithelial neoplasia or
cancer) [31,32], whereas another study analyzed morphologically
normal cervices. In the study by Leonard et al., the authors reported the
presence of HPV in 42% of morphologically normal cervices using in
situ hybridization and PCR-based methods [33]. Because persistence of
HPV in the absence of clinical disease does not preclude viral activities
acquired for genome maintenance, such as replication of the viral
genome below detectable levels or production of viral transcripts, p16
and E4 is often used as markers of a productive infection. However,
although the authors reported the absence of p16 and E4 like in the
present study, it is unclear if the findings reported by Leonard et al.
reflect “true” latency as cervical cytology samples were not analyzed for
the presence of HPV. Thus, it is unclear if the high HPV prevalence
Fig. 3. Distribution of HPV in the human uterine cervix.
Each pie chart illustrates the cervix seen from the vagina
and the location of the HPV-positive test results. The
central white circle illustrates the cervical orifice (i.e.
opening to the uterine cavity). Each large pie piece re-
presents a 3-mm block and each smaller slice represents a
whole tissue section set tested by SPF10 PCR.
Table 2
Probability of detecting HPV in a cervix, by the proportion of cervical tissue
sampled and the percentage of HPV-positive sets in a given cervix.
Percentage of sets tested
5 10 15 20 25
Assumed percentage of HPV-positive
sets
0.1 0.5 1.0 1.5 2.0 2.5
0.5 2.5 4.9 7.2 9.5 11.8
1.0 4.9 9.6 14.0 18.2 22.2
2.0 9.6 18.3 26.1 33.2 39.7
5.0 22.6 40.1 53.7 64.2 72.3
7.5 32.3 54.1 68.9 79.0 85.8
10.0 41.0 65.1 79.4 87.8 92.8
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reported in their study may be a result of an active HPV infection (that
would have been picked up by routine HPV testing of a cervical cy-
tology specimen), rather than a latent HPV infection, or a combination.
In our study, both patients were HPV-negative and had normal cytology
on a liquid based cytology sample obtained prior to surgery. Ad-
ditionally, we found no evidence of E4 and p16 on slides adjacent to
HPV-positive sections, which suggest that the infection is non-produc-
tive and might represent a latent HPV infection. Unfortunately, we are
unable to determine if the HPV detected represents a new infection in
it's early stage, a regressing infection, or a “true” latent infection, as
there is currently no molecular marker available that is able to distin-
guish between these stages. We cannot exclude that the HPV infection
in patient 2 may represent an early infection because of recent new sex
partners; however, we find a new early infection unlikely in patient 1,
as there was no reporting of new sex partners within the preceding
10–15 years.
4.1. Strengths and limitations
Our data demonstrates that studies attempting to use hysterectomy
samples to estimate a woman-level prevalence of latent HPV must use a
very sensitive PCR-based HPV assay with intensive sampling across the
tissue due to the focal nature of the infections. Sampling of even 25% of
the cervix is likely to result in a false negative result if the latent infection
density is<2%. In the present study we used the SPF10 PCR followed by
DEIA/LIPA25, which can detect 1–44 HPV DNA copies per PCR reaction
by amplifying a fragment of only 65 base pairs. However, we cannot rule
out that some HPV-positive sections may have been missed, particularly
because the viral copy number is likely very low during latency [3], and
because we used formalin-fixed, paraffin-embedded tissue. The process
of formalin fixation and paraffin embedding is known to cause DNA cross
linkages, change of DNA structure, and breaks, which may result in
subsequent difficulties with PCR [34,35]. The short PCR fragment of 65
base pairs would have reduced the risk of missing positive samples be-
cause of DNA damage due to formalin fixation. Furthermore, we ac-
knowledge the risk of contamination, especially when dealing with a low
copy number HPV infection. Thus, we found it critical to rule out con-
tamination as an explanation for our positive test results. In the present
study, we therefore included negative controls in all steps from the
cutting of the block to PCR, DEIA, and LiPA25. All negative controls were
negative, and we therefore find contamination unlikely.
5. Conclusion
In conclusion, we found molecular evidence of a non-productive and
non-transforming HPV infection in two patients using an extensive
sampling and testing procedure. These results support the findings of
previous clinical and epidemiological studies that HPV is able to es-
tablish latency in the human uterine cervix. Future studies are required
to determine if this controlled HPV infection is able to reactivate to
productive and/or transforming infection, as our data suggest that
women exiting screening with a negative HPV test may indeed continue
to harbor high-risk HPV infections.
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